Lilly Oncology Medical (@LillyOncMed)
@LillyOncMed
Dedicated to communicating the latest science & disease state education from Lilly Oncology. Intended for U.S. HCPs. Community Guidelines:
597 正在关注 6.6K 粉丝
🔬 FRAmework 01 | Now Enrolling
A phase 3 trial evaluating a FRα targeting ADC in patients with ovarian cancer.
Key details:
- PSOC and PROC
- All FRα expression levels
- Prior mirvetuximab permitted
Click below to learn more about trial details and enrollment
显示更多
🔬 FRAmework-01 | Now Enrolling
A phase 3 trial evaluating a FRα-targeting ADC in patients with Ovarian Cancer.
Key details:
- Enrolling PSOC and PROC
- All FRα expression levels
- Allows prior mirvetuximab
Click the image for trial & enrollment info
显示更多
🩺SUNRAY 01 Part A | KRAS NSCLC Phase 3 Trial | Now Enrolling
A phase 3 trial evaluating a targeted, PD 1 inhibitor–based approach in treatment naïve KRAS G12C mutant NSCLC.
Click below for trial details & enrollment info
显示更多
